RETENSION PHARMACEUTICALS IN
RTSNNASDAQTrading Snapshot
- Day Range
- $9.61 β $12.49
- 52-Week Range
- $9.23 β $18.64
- Volume (shares)
- 6,437
- Avg Volume (shares)
- β
- Shares Outstanding
- 3.8M
- Next Earnings
- 2027-02-17
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- β
- P/S Ratio
- β
- EPS (TTM)
- β
- Dividend Yield
- β
RETENSION PHARMACEUTICALS IN
RTSNFinancial history unavailable.
About RETENSION PHARMACEUTICALS IN
Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

Retension Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
IPO completed in October 2026 to support the continued development of RTN-001 for uncontrolled and resistant hypertension, affecting ~30 million Americans Upsized IPO generated $51.75 million in gross proceeds Topline da

Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
FALLS CHURCH, Va., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (βRetensionβ or the βCompanyβ), a clinical-stage biopharmaceutical company focused on developing medicines for the treat

Retension Pharmaceuticals Announces Pricing of Initial Public Offering
FALLS CHURCH, Va., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (βRetensionβ or the βCompanyβ), a clinical-stage biopharmaceutical company focused on developing medicines for the treat